Sanofi $SNY Shares Acquired by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,495,348 shares of the company’s stock after buying an additional 856,742 shares during the period. Sanofi makes up approximately 3.4% of Mondrian Investment Partners LTD’s holdings, making the stock its 6th largest position. Mondrian Investment Partners LTD’s holdings in Sanofi were worth $217,845,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in SNY. Brighton Jones LLC boosted its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the period. AQR Capital Management LLC boosted its stake in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after buying an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after buying an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Sanofi by 36.1% during the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after buying an additional 875 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $44.29 on Friday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company has a market cap of $108.02 billion, a P/E ratio of 12.37, a PEG ratio of 1.09 and a beta of 0.35. Sanofi has a 52 week low of $42.33 and a 52 week high of $53.03. The company has a 50-day moving average price of $45.58 and a 200 day moving average price of $47.23.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be given a dividend of $2.4225 per share. This represents a dividend yield of 559.0%. The ex-dividend date is Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is presently 49.16%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SNY shares. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Morgan Stanley set a $52.00 target price on shares of Sanofi in a research note on Friday, May 1st. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.